This site is intended for health professionals only

Shire Files Suit against Actavis Elizabeth LLC and Actavis


Biopharmaceutical company, Shire, announces that its subsidiary Shire LLC has filed a lawsuit.

in the U.S. District Court for the District of Delaware against Actavis Elizabeth LLC and Actavis Inc. (collectively “Actavis”) for the infringement of U.S. Patent Nos. 5,854,290 (the ‘290 patent), 6,287,599 (the ‘599 patent), and 6,811,794 (the ‘794 patent).

The lawsuit results from an Abbreviated New Drug Application (ANDA) filed by Actavis for generic versions of 1 mg, 2 mg, 3 mg and 4 mg guanfacine hydrochloride extended release tablets, INTUNIVTM, which seeks to market such generic products before the expiration of the ‘290, ‘599, and ‘794 patents.  The regulatory exclusivity period for INTUNIV runs through September 2, 2012.

For more information, please click the link below:

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine